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Abstract A meningococcal serogroup A polysaccharide/tetanus toxoid conjugate vaccine (PsA-TT)
(MenAfriVacTM) is being deployed in countries of the African meningitis belt. Experience with other
polysaccharide/protein conjugate vaccines has shown that an important part of their success has been
their ability to prevent the acquisition of pharyngeal carriage and hence to stop transmission and
induce herd immunity. If PsA-TT is to achieve the goal of preventing epidemics, it must be able to
prevent the acquisition of pharyngeal carriage as well as invasive meningococcal disease and whether
PsA-TT can prevent pharyngeal carriage needs to be determined. To address this issue, a consortium
(the African Meningococcal Carriage (MenAfriCar) consortium) was established in 2009 to
investigate the pattern of meningococcal carriage in countries of the African meningitis belt prior to
and after the introduction of PsA-TT. This article describes how the consortium was established, its
objectives and the standardised field and laboratory methods that were used to achieve these
objectives. The experience of the MenAfriCar consortium will help in planning future studies on the
epidemiology of meningococcal carriage in countries of the African meningitis belt and elsewhere.
keywords Africa, MenAfriCar, meningococcal carriage, meningococcal vaccines, meningococcus,
Neisseria meningitidis
Introduction
For at least 100 years, epidemics of meningococcal menin-
gitis have occurred frequently but unpredictably in a region
of the Sahel and sub-Sahel known as the African meningitis
belt (Lapeyssonie 1963). Most African epidemics have
been caused by meningococci belonging to serogroup A
(Greenwood 1999) but outbreaks caused by meningococci
belonging to serogroup C, W or X meningococci have been
reported (Broome et al. 1983; Decosas & Koama 2002;
Boisier et al. 2007; Halperin et al. 2012).
For the past three decades, control of epidemic menin-
gococcal disease in the African meningitis belt has relied
upon reactive vaccination with a polysaccharide vaccine
once the incidence of cases in a district or region has
passed a critical incidence threshold (WHO Working
Group 1998). When reactive vaccination with polysac-
charide vaccines has been deployed early in an epidemic,
it has saved many lives but it has not reduced the fre-
quency of epidemics because polysaccharide vaccines
induce protection of limited duration, especially in chil-
dren, and have little or no impact on carriage (Dellicour
& Greenwood 2007). Polysaccharide/protein conjugate
vaccines are likely to be more successful in preventing
epidemics because they induce immunological memory
and decrease pharyngeal carriage.
Widespread deployment of serogroup C meningococcal
conjugate vaccines in Europe has reduced serogroup C
meningococcal disease and carriage and led to elimina-
tion of the serogroup C meningococcal clone responsible
for outbreaks in the UK (Maiden & Stuart 2002; Trotter
et al. 2004). Unfortunately, Africa has had to wait many
years longer than the industrialised world for an afford-
able meningococcal conjugate vaccine that could prevent
serogroup A epidemics. However, following an innova-
tive and highly successful development programme under-
taken by the Meningitis Vaccine Project (MVP), a
collaboration between WHO and PATH, a monovalent
serogroup A conjugate (PsA-TT) (MenAfriVacTM)),
manufactured by the Serum Institute of India, was
licensed in India in 2009 and pre-qualified by WHO in
2010 (Frasch et al. 2012). At the end of that year, mass
vaccination programmes in subjects aged 1–29 years were
launched in Burkina Faso, Mali and Niger (Djingarey
et al. 2012). Recent reports suggest that the vaccine has
been highly effective in reducing serogroup A meningo-
coccal disease and carriage in Burkina Faso (Kristiansen
et al. 2012; Novak et al. 2012).
PsA-TT, like other conjugate vaccines, was pre-
qualified on the basis of its safety and immunogenicity
(Sow et al. 2011) without an efficacy trial being under-
taken. Therefore, post-implementation evaluation of its
impact on both meningococcal disease and carriage is
essential. Consequently, in 2009, the African Meningo-
coccal Carriage (MenAfriCar) consortium was established
to measure the prevalence of meningococcal carriage
across the African meningitis belt using standardised
techniques before and after introduction of PsA-TT. This*Details are provided in Box 1.
968 © 2013 The Authors. Tropical Medicine and International Health published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Tropical Medicine and International Health doi:10.1111/tmi.12125
volume 18 no 8 pp 968–978 august 2013
article describes how the consortium was established, its
objectives and the methods used to meet these objectives.
Creation of the African meningococcal carriage
consortium
Several years before a serogroup A meningococcal conju-
gate vaccine became a reality, a group of scientists inter-
ested in meningococcal disease in Africa began discussions
on the importance of measuring the impact of such a
vaccine on carriage and the challenges that this would
pose. Few meningococcal carriage studies have been
conducted in the African meningitis belt in recent years
(Leimkugel et al. 2007; Mueller et al. 2007; Kristiansen
et al. 2011), and earlier studies gave very varied results
because they had been restricted to a single site, had been
conducted at different times of the year and/or used a vari-
ety of methods (Trotter & Greenwood 2007). Therefore, it
was agreed that the best way forward would be the forma-
tion of a group that could carry out carriage studies across
the meningitis belt before and after introduction of the
new vaccine using standardised methods. Consequently,
the African Meningococcal Carriage (MenAfriCar) consor-
tium, comprising seven African and 12 northern partners
(Box 1), was established formally in 2009.
Box 1. Members of the African Meningococcal
Carriage consortium.
African Partners: Armauer Hansen Research Institute,
Addis Ababa, Ethiopia; Centre de Recherche Medical et
Sanitaire (CERMES), Niamey, Niger; Centre pour les
Vaccins en Developpement (CVD), Bamako, Mali;
Institut de Recherche pour le Developpement (IRD),
Dakar, Senegal; Centre de Support en Sante Internatio-
nale (CSSI), N’Djamena, Chad; Navrongo Health
Research Centre, Navrongo, Ghana; University of
Maiduguri (Department of Community Medicine),
Maiduguri, Nigeria. Northern Partners: Agence de
Medecine Preventive (AMP), Paris, France; Centers for
Disease Control (Division of Bacterial Diseases), Atlanta,
USA; Health Protection Agency (Vaccine Evaluation
Unit), Manchester, UK; Institut Pasteur (Unite Infections
Bacteriennes Invasives), Paris, France; Institut de
Medecine Tropical du Service de Sante des Armees
(IMTSSA), Marseille, France; London School of Hygiene
& Tropical Medicine, London, UK; Norwegian Public
Health Institute, Oslo, Norway; PATH (Meningitis
Vaccine Project), Ferney, France; Swiss Tropical and
Public Health Institute, Basle, Switzerland; University of
Bristol (Department of Social Medicine), Bristol, UK;
University of Oxford (Department of Zoology), Oxford,
UK; World Health Organisation, Geneva, Switzerland.
Objectives of the consortium
The objectives of the MenAfriCar consortium are sum-
marised in Box 2.
Box 2. Objectives of the African Meningococcal
Carriage consortium
Determination of the prevalence of meningococcal
carriage in seven countries extending across the
meningitis belt from east to west (Ethiopia, Chad,
Nigeria, Niger, Ghana, Mali and Senegal) prior to the
introduction of PsA-TT.
Characterisation of risk factors for carriage of
meningococci in countries of the African meningitis belt.
Investigation of the spread of meningococci within
households.
Measurement of the impact of PsA-TT on serogroup
A meningococcal carriage.
Measurement of serogroup A meningococcal antibody
concentrations by ELISA and bactericidal assays in coun-
tries across the meningitis belt.
Organisation and management of the consortium
Each centre identified a principal investigator whose team
has been supported by two epidemiologists and a data
manager based at the London School of Hygiene &
Tropical Medicine (LSHTM) and by a laboratory
manager based at the Centre for Vaccine Development
(CVD), Bamako, Mali. A small secretariat was
established at LSHTM to manage the project’s finances,
order supplies, organise meetings and coordinate
communications. Clinical trial monitors have visited each
centre on at least three occasions during the course of
carriage surveys, and an international advisory committee
has provided overall guidance on the conduct of the
project.
Communications officers, assisted by a small commit-
tee, were established at the beginning of the project at
each African centre and, after formal training, given
responsibility for informing study communities about the
nature and purpose of the carriage studies, informing
these communities of their findings and for communicat-
ing results to officials of the Ministry of Health, WHO
and other interested parties. A consortium newsletter was
developed and circulated widely. An open access website
(www.menafricar.org) was established as well as a
separate, password protected site, accessible only to
consortium members, which holds all operational
documents and which hosts a discussion forum. Each
centre established a crisis management committee to
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manage any unforeseen events, such as a death occurring
during the course of a carriage study.
The study was approved by the LSHTM Ethics
Committee and by the ethics committees of each of the
African partner institutions with the exception of Chad,
which does not have a formal ethical committee, where
approval was granted by a committee set-up to oversee
MenAfriCar studies by the Ministry of Health. The study
was registered with ClinicalTrials.gov (NCT01119482).
Study design, populations and epidemiological
methods
Introduction
Carriage studies were conducted in seven countries within
the African meningitis belt: Chad, Ethiopia, Ghana, Mali,
Niger, Nigeria and Senegal (Figure 1). Both urban and
rural study sites were selected in each country. The tim-
ing of carriage surveys is shown in Figure 2.
Pilot studies. Pilot studies were undertaken at each
centre in 2009 or 2010 in a convenience sample of 250
schoolchildren to familiarise the investigators with the
standard operating procedures and to determine the
optimum method of collecting pharyngeal swabs for the
isolation of meningococci. It was found that collecting
swabs touching both the posterior pharynx and the
tonsils was more effective at isolating Neisseria
meningitidis than swabbing just the posterior of the
pharynx (Basta 2011); thus, this technique was used in
all subsequent surveys.
A further pilot study of the methods to be used in
household studies was conducted in 2010 in which a
sample of 400 individuals resident in over 100 house-
holds in Bamako, Mali, were screened for carriage and
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Figure 2 Gantt chart showing the timing of different MenAfriCar carriage surveys.
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200 residents of 20 households followed prospectively for
6 months.
Pre-vaccination cross-sectional surveys
Three cross-sectional surveys, two in the rainy and one in
the dry season, were undertaken between July 2010 and
July 2012 (Figure 2) in each country except for Nigeria,
where the last survey could not be carried out because of
political instability. A representative sample frame was
obtained either from an updated, ongoing demographic
surveillance system (DSS) or from a census conducted
specifically for the study. Multistage sampling was used.
Study households were selected by simple random
sampling from the DSS or census. Within selected
households, individuals stratified by age group (<1 year,
1–4 years, 5–14 years, 15–29 years and 30 years or
more) were randomly selected until the required sample
size had been reached.
In Mali and Niger, the first survey included 5 000 sub-
jects. In Chad, the second and third surveys included at
least 5 000 subjects. All other pre-vaccination surveys
included approximately 2 000 subjects. The only exclu-
sion criteria for these surveys were lack of consent or
being too ill to participate. Once consent and assent were
obtained, a structured questionnaire1 was completed by
the head of the household to obtain information on
potential risk factors for carriage at the household level.
Each study participant or their guardian completed a
short questionnaire, which collected demographic infor-
mation and information on potential risk factors for
meningococcal carriage at the individual level. A pharyn-
geal swab was obtained and plated out directly in the
field. A 5 ml blood sample was obtained from 400 ran-
domly selected, age-stratified subjects aged 6 months or
more in each study area during the first cross-sectional
survey.
The rate of recruitment during cross-sectional surveys
was determined largely by the degree of dispersal of the
study subjects and by the ability of laboratory staff to
handle the microbiological plates that they received. This
worked out at a maximum of 100 samples a day for an
individual laboratory with an average of around 50
samples a day.
Household contact surveys
Longitudinal household surveys were triggered by the
identification of an index carrier during a cross-sectional
survey. Within 4 weeks of the identification of a carrier,
the household of these subjects was visited and all house-
hold members were invited to participate in a follow-up
study. Once a household had consented to join the study,
pharyngeal swabs were collected from household mem-
bers twice a month for 2 months and then monthly for a
further 4 months. During the first visit, the head of the
household was asked to complete a detailed household
questionnaire. Household members were asked to provide
similar information to that requested from volunteers in
the cross-sectional surveys. Height and weight of each
household contact over 6 months of age who agreed to
join the study were measured, and a pharyngeal swab
and a 5 ml blood sample were obtained.
Post-vaccination surveys
It was planned initially to undertake post-vaccination
surveys in Mali and Niger, early PsA-TT adopter
countries, but as no serogroup A meningococci were
detected in pre-vaccination surveys in either of these
countries, this plan was not pursued. Instead, a
post-vaccination survey in approximately 6 000 individu-
als was conducted in 2012 in Chad, where serogroup
A meningococci had been isolated during the cross-
sectional survey conducted prior to vaccination of a part
of the country at the end of 2011.
Sample size
Determination of sample sizes for these carriage studies
was difficult because of the variability in carriage preva-
lence reported in previous African surveys (Trotter &
Greenwood 2007). For the pre- and post-vaccination
comparison, a sample size of 5 000 was chosen on the
grounds of expected carriage rates and logistic
constraints. With a baseline serogroup A carriage preva-
lence of 1% (a figure assumed to be conservative), a
study of this size would have 80% power to show a 50%
reduction in carriage following vaccination. In the centres
where the introduction of PsA-TT was not imminent, the
objectives of the carriage surveys were largely descriptive,
but a sample size of 2 000 was deemed large enough to
enable meaningful comparisons to be made by country,
site (urban vs. rural), season and age group. Based on
previous experience with cross-sectional serological
surveys, it was considered that an age-stratified sample of
800 per centre would allow meaningful comparisons of
serogroup-specific IgG and serum bactericidal antibody
concentrations by age and across countries.
There are no data on the rate of meningococcal acqui-
sition in household contacts in Africa to assist in the
1
Copies of risk factor questionnaires are available from the
authors.
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design of the household studies. An informed presump-
tion was that the household acquisition rate would be
around 1% per month, but some pragmatic decisions
were taken regarding the number of households that the
field teams had the capacity to recruit and follow.
Laboratory methods
Isolation and characterisation of meningococci
Pharyngeal swabs were plated directly onto modified
Thayer–Martin agar plates in the field and taken to the
laboratory within 6 h of collection where they were incu-
bated for 24–48 h at 37 °C in 5% CO2. During a pilot
study, one or two colonies on the Thayer–Martin plate
with a morphology typical of Neisseria species were
selected for Gram staining and oxidase testing (Beckton
Dickinson, Oxford, UK). Oxidase-positive, Gram-
negative colonies were then subcultured onto one blood
agar plate containing 7% defibrinated sheep’s blood and
these plates incubated for 18–24 h at 37 °C in 5% CO2
(Martin et al. 1974). Bacteria from the blood agar plate
were serogrouped by slide agglutination with meningo-
coccal serogroup A, W and X antisera (Difco, Becton
Dickinson, Oxford, UK). A fine suspension of the test
organism was made in 10 ll of phosphate-buffered saline
(PBS) on a clean glass slide, and 10 ll of antiserum was
added to the bacterial suspension. The slide was rocked
for 4 min before the agglutination pattern was read.
For the main studies, one suspected colony with a
morphology typical of a Neisseria species was subcul-
tured onto two blood agar plates and the plates incu-
bated for 18–24 h at 37 °C. Bacteria from one blood
agar plate were tested for oxidase activity and then Gram
stained. Oxidase-positive, Gram-negative diplococci were
then tested for c-glutamyl-transferase activity (GGT)
(Rosco Diagnostica, Taastrup, Denmark) (Takahashi
et al. 2004), b-galactosidase activity with ortho-
nitrophenyl-b-D-galactopyranoside (ONPG) (Rosco Diag-
nostica,Taastrup, Denmark) for identification of N. lact-
amica and butyrate esterase activity (Tributyrin) (Rosco
Diagnostica, Taastrup, Denmark) for distinguishing
between N. meningitidis and Moraxella species (Perez
et al. 1990). To carry out these tests, a loopful of an
18- to 24-h culture of the test organism grown on blood
agar was suspended in 250 ll of normal saline and the
suspension incubated with the appropriate enzyme
substrate at 37 °C for 4 h before observation for the
indicative colour change. Isolates with the profile GGT
positive, ONPG negative and tributyrin negative were
characterised as presumptive N. meningitidis and sero-
grouped by slide agglutination using serogroup A, W, X
and Y antisera (Difco, Becton Dickinson, Oxford, UK). A
fine suspension of the test organism was made directly in
each of the four antisera on a clean glass slide and the
slide rocked for 1 min. Each antiserum was tested with a
positive and negative control bacterium. A sample was
assigned to a specific serogroup only if visible agglutina-
tion or clumping of the bacteria, with clearing of the
background bacterial suspension on the slide, was
observed within 1 min (World Health Organization
2009). Bacterial colonies from the second agar plate were
used for DNA preparation by boiling the bacteria from
half a plate suspended in PBS for 20 min in a water bath.
The rest of the bacteria on the same agar plate were
prepared for long-term storage on beads (Microbank, Pro
Lab Diagnostics, Bromborough, UK), following the
manufacturers’ instructions, and the sample stored at
80 °C.
To test the ability of the participating laboratories to
correctly identify Neisseria growing on Thayer–Martin
agar plates, fifty samples from the selective medium from
which no Neisseria were identified as well as fifty samples
from organisms identified as oxidase-positive, Gram-
negative diplococci at each site were sent to the WHO
Coordinating Centre at the Institut Pasteur, Paris, for con-
firmation of the results obtained at the African centres. A
description of the quality control procedures adopted for
this study will be presented in a subsequent paper.
Molecular characterisation of Neisseria
Boiled suspensions of Gram-negative diplococci were
separated into four aliquots. One aliquot was sent to the
University of Oxford for molecular analysis, the second
used on site for identification of N. meningitidis by PCR
and the remaining two aliquots archived.
Following a workshop at CERMES on PCR detection
and genogrouping of meningococci and regular follow-up
visits by the laboratory coordinator, six of the seven
MenAfriCar centres are now able to conduct a por
A PCR test to confirm the identity of isolates of
N. meningitidis identified by routine microbiology. If the
por A PCR test is positive, an A, X, W multiplex
genogrouping PCR is performed. If this first multiplex
PCR is negative, a singleplex Y genogrouping PCR is
performed. Ready-to-load master mix containing Hot
Start Taq polymerase (Solis Byodine, Tartu, Estonia) was
chosen as the PCR mixture to render the PCR technique
as simple as possible and because this enzyme-containing
master mix can be transported at room temperature. The
7.5 mM MgCl2 master mix was adjusted to 11 mM MgCl2
to optimise the technique. Prior to the introduction of
PCR testing as a routine procedure, each site underwent
972 © 2013 The Authors. Tropical Medicine and International Health published by John Wiley & Sons Ltd.
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cross-validation of the technique, comparing results of
approximately 50 samples with results obtained at the
University of Oxford.
On arrival in Oxford, heat-killed bacterial cell suspen-
sions are archived at 20 °C and entered on a BIGSDB
database (Jolley & Maiden 2010) for subsequent hierar-
chical analysis using a custom-built high-throughput
Sanger sequencing pipeline. All sequence data are submit-
ted directly into this database and the results interpreted
automatically by querying with reference sequences. The
first stage of characterisation of Neisseria species is done
with an assay based on ribosomal multilocus sequence
typing (rMLST) (Bennett et al. 2012; Jolley et al. 2012),
which indexes variation in a 413-bp fragment of a gene
encoding a ribosomal protein subunit (rplF) (Bennett JS,
Watkins ER, Jolley KA, Harrison OB, Maiden MC,
unpublished). The rplF gene fragment is amplified and
sequenced. A null result (no sequence) is consistent with
the specimen not containing a member of the genus
Neisseria; sequences obtained from positive specimens are
diagnostic for each Neisseria species. Isolates that are
rplF negative are characterised by sequencing a fragment
of the 16S (small subunit) rRNA gene to confirm genus
or lack of bacterial DNA suitable for PCR amplification.
All samples are also tested with an assay that sequences
the capsule null (cnl) region of the meningococcal chro-
mosome (Claus et al. 2002). This region is present in
genetically characterised meningococci without a capsule
and in all Neisseria species other than meningococci.
Samples that are identified as meningococci with the rplF
assay, but which are negative for cnl, are characterised
for genogroup by amplification and sequencing of a frag-
ment of the ctrA gene, which is present in all meningo-
cocci with a capsule synthesis (cps) region. Sequences of
these fragments identify most genogroups (A, E, I, K, L,
X, Z), with the organisms with cps regions encoding
sialic acid-containing capsules (B, C, W, Y) identified by
further sequencing the cssD gene in their cps region
(Harrison et al. 2013).
The approach taken to the isolation and characterisa-
tion of N. meningitidis from pharyngeal swabs is
summarised in Figure 3.
Serology
Two serogroup A meningococcal antibody assays have
been used in the MenAfriCar studies, a quantitative
enzyme-linked immunosorbent assay (ELISA) (Carlone
et al. 1992) and a serum bactericidal antibody assay that
uses rabbit complement (rSBA) Maslanka et al. 1997).
To facilitate transfer of the ELISA technique from the
Health Protection Agency (HPA) Vaccine Evaluation Unit
(VEU), Manchester, UK to Africa, two workshops were
organised, one at the HPA VEU predominantly for scien-
tists from the English-speaking countries and the other at
CVD, Mali, for those from French-speaking countries.
The ELISA has been implemented successfully at six of
the seven MenAfriCar centres.
The ELISA used for the MenAfriCar studies is a classi-
cal indirect assay involving serial dilutions with each test
serum assayed in duplicate. Although simple to perform,
interpretation of the results of the assay requires sound
mathematical and statistical knowledge. Standard serum
CDC 1992, with an assigned serogroup A-specific IgG
concentration of 91.8 lg/ml, was used as the reference
serum (Holder et al. 1995). In addition, a locally
calibrated positive control serum sample was included
on each plate. The lower limit of quantitation for this
ELISA is 0.19 lg/ml. Consistency in the results obtained
following testing of the control samples on at least
40 occasions was required before progression to
cross-validation.
Before analysis of samples collected during the cross-
sectional surveys commenced, the results on 50 samples
tested on site and at the HPA VEU were cross-validated.
A correlation coefficient of >0.9 was required before a
centre progressed to testing of survey samples (Lin 1989).
Some centres needed to undergo cross-validation on more
than one occasion before meeting this target. Regular
monitoring visits and constant support from the
MenAfriCar laboratory team were needed to achieve this
important step.
As the rSBA is a more complex technique than ELISA
and requires expensive equipment, it has been undertaken
at only two of the MenAfriCar centres (CVD, Mali and
CERMES, Niger), one of which (CERMES) already had
experience with this technique. SBA assays were
performed using the CDC F8238 strain of serogroup A
meningococcus (phenotype A: 4,21: P1.20,9, L11), as
described previously (Maslanka et al. 1997). The
complement source was serum from 3- to 4-week-old
rabbits (Pel Freez Biologicals, Wisconsin). Titres were
expressed as the reciprocal serum dilution yielding 50%
killing after 60-min incubation. Cross-validation of the
rSBA with results obtained at the HPA VEU was
undertaken on 50 samples. Agreement for routine testing
to proceed required that the results of testing on site and
at the VEU, Manchester, to be within a minus one, plus
one range in titre. Some of the serum samples used for
cross-validation had to be excluded from the panel
because of inconsistent results obtained after performing
runs in triplicate within each laboratory. This is thought
to have been due to the presence of low avidity
antibodies that may have been naturally induced.
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Standardisation of the SBA technique proved difficult,
and Mali had to repeat the cross-validation exercise
twice.
Data management
Various systems for data management that required
construction of local and a central database were
considered, including manual double entry, the
open-source electronic data capture system Open Clinica
(Paulsen et al. 2012) and TeleForm, an automated form
processing system for data management (TeleForm
software: version 10.4.1 1991-2009, Autonomy). After
preliminary tests at several African centres, was TeleForm
chosen. This data management system allows study forms
to be specially designed, scanned after completion,
automatically read through a combination of optical/
intelligent character recognition, optical mark recognition
and barcode recognition and then verified before being
exported to a local database. It also allows rapid data
entry and reduces opportunities for error, especially for
optical mark recognition variables such as check boxes.
For harmonisation purposes and to facilitate technical
support, centres were provided with similar scanning and
computing equipment pre-loaded with TeleForm.
To ensure that all centres used the same study forms,
were developed centrally in both English and TeleForm
French. A label form was designed, which could be popu-
lated automatically with study IDs and printed in
self-adhesive label sheets for use in the laboratory. Local
and central databases were designed to accommodate the
study forms. A separate database module was developed
centrally to automatically populate the main study
database with genetic laboratory results from the Oxford
BIGS database (Jolley & Maiden 2010). Additional data
validation software packages were developed and shared
between centres to harmonise local data cleaning.
Training sessions on the new system were organised for
data managers and field workers, and continuous
technical support was provided to them throughout the
study.
Capacity development
An important component of the activities of the
MenAfriCar consortium has been strengthening the
From each swab collected in the field:
Bacteria grown on Thayer Martin (TM) plates
Incubate plates at 35–37 °C in 5% CO2 24–48 h
Selection of one typical colony per TM plate
Bacteria grown on two different Blood Agar Plates (BAP)
Bacteria grown from first BAP
Oxidase test (Ox)
Gram stain on Ox positive test
ortho-Nitrophenyl-β-galactoside (ONPG) test 
Detection of g-glutamyl transpeptidase (GGT) activity
Tributyrin (Trib)
N . meningitidis Ox pos/Gram neg diplo/ONPG neg/GGT pos/Trib neg 
selected
Slide Agglutination Sero-Grouping test (SASG) with A, W first then X and Y 
antisera
Por A PCR amplification
A, X and W multiplex PCR or Y singleplex PCR amplification of por A 
positive samples
Oxidase positive Gram negative diplococci 
Remove three loopful of bacterial colonies from 2nd
BAP and inoculate into cryopreservative fluid of one 
beads vial 
DNA extraction: Harvest the rest of the bacteria into1 
ml PBS/Boil ALL bacteria for 20 min to release the 
bacterial DNA/Allow sample to cool down/Aliquot in 
4 × 1.5 ml microtubes/Store at
–80 °C
Shipment of 1 aliquot to University of Oxford 
rplF gene sequenced Neisseria speciation. rplF 
negative isolates undergo 16S rRNA. 
On confirmed N. meningitidis identification of all 12 
serogroups and cnl. Multiplex PCR and sequencing 
reaction for 9 variants of ctrA gene serogroups E, Z, 
X, L, I, K, A and H or presence of sialic acid capsule.
Figure 3 Flow diagram indicating the procedure for isolating and characterising Nesisseria meningitidis isolates from oropharyngeal
swabs.
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research capacity of the participating African centres.
Since 2010, 13 African scientists supported by the
MenAfriCar consortium have received formal training in
epidemiology, public health, microbiology, data or pro-
ject management. Four scientists have been supported to
undertake a MSc course, three have attended a short
course on genomics and clinical microbiology at the
Sanger Centre, Cambridge, UK, and two spent several
months at the University of Oxford gaining practical
experience in molecular microbiological techniques.
Training in data management for scientists from Ethiopia
has been provided at LSHTM and at the KEMRI-
Wellcome Laboratories, Kilifi, Kenya.
In addition to the PCR and serology training work-
shops mentioned above, a one-week course on good clini-
cal and laboratory practice (GCP and GLP) was
organised by LSHTM and the Contract Laboratory Ser-
vices (CLS) in Johannesburg, South Africa. Formal train-
ing for the study teams in microbiology and serology has
been supplemented by regular visits to each centre by the
senior scientists participating in the project.
Discussion
The study described in this article has been the first large,
multicountry meningococcal carriage study conducted in
the African meningitis belt using a standardised study
protocol. Many lessons were learnt during the course of
the project, which involved both francophone and anglo-
phone countries, which could be of value in the design of
future carriage studies.
The unpredictability of meningococcal infection in the
African meningitis belt makes forward planning of epide-
miological studies difficult. Therefore, the consortium
initiated carriage studies in seven countries across the
meningitis belt in the expectation that the serogroup A
meningococcus would be circulating in at least one of
these countries during the period of the study, as proved
to be the case. This flexibility allowed the consortium to
adapt the design of its studies as additional information
about the prevalence, and serogroup of carriers was
obtained. Specifically, post-vaccination activities were
transferred from Mali and Niger to Chad when it
emerged that with the exception of northern Cameroon,
this was the only country in the African meningitis belt
with substantial transmission of serogroup A meningo-
cocci in 2011 and 2012.
Carriage of N. meningitidis is relatively uncommon in
the general population between epidemics, necessitating
large samples to demonstrate differences in carriage rates
between populations or over time. On the basis of the
limited information available, we estimated that the
overall carriage rate of N. meningitidis would be around
10% and that of serogroup A, meningococci would be
about 1% outside epidemic periods. These estimates were
over optimistic, and a serogroup A carriage rate
approaching 1% was found only in rural areas of Chad.
It is likely that the MenAfriCar carriage studies have
been undertaken at a time of a naturally low level of
serogroup A meningococcal transmission in the African
meningitis belt, but experience from these studies indi-
cates that future carriage studies to monitor the impact
of conjugate vaccines in the African meningitis belt are
likely to require many thousands of subjects to ensure
sufficient power to detect significant differences between
groups.
All the participating African centres had previous expe-
rience of field studies, and no major problems were
encountered in the implementation of the carriage
surveys. Selection of households for inclusion in the
carriage studies was relatively straightforward at the sites
where a demographic surveillance system was in place
but required a preliminary census in those that did not.
Practical problems were encountered when households
selected for inclusion in a survey were widely scattered,
requiring the study team to repeatedly pack up and move
the equipment needed for collection of swabs and blood
samples to another site, slowing down the daily rate of
recruitment. Local solutions to this problem were
developed, which included bringing individuals selected
for inclusion in the survey to a common meeting point
(Ghana) and deployment of up to 16 field teams to work
concurrently (Chad). The rate at which subjects could be
recruited was limited by the rate at which a single labora-
tory could handle the samples collected. This proved to
be about 100 samples a day. As expected, the speed and
efficiency of carriage surveys improved progressively
during the course of the study.
To ensure that results obtained at each of the seven
centres in the consortium could be compared, it was
essential that reproducible and standardised laboratory
methods were used at each centre. Ensuring that, this
was the case proved more difficult than had been antici-
pated originally. Quality control of both microbiological
and serological assays was facilitated through support
from the northern partners in the consortium. Quality
control in microbiological techniques was helped greatly
by the molecular characterisation of isolates at the
Centre de Recherche Medicale et Sanitaire (CERMES),
Niamey, the Norwegian Institute of Public Health
(NIPH), Oslo and at the University of Oxford. This
provided early indication of problems at some centres
with both speciation and serogrouping of neisserial
isolates. This allowed remedial actions, including
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introduction of biochemical testing after the pilot studies
and modification of the serogrouping agglutination assay
followed by training workshops after the first cross-
sectional survey, to be undertaken early in the project.
An additional wet season survey was undertaken, a dry
season survey postponed for 12 months and quality con-
trol procedures reviewed in the light of early experiences.
The importance of a detailed quality control procedure
for studies of the kind undertaken by the MenAfriCar
consortium has recently been stressed by Kristiansen
et al. (2012) based on their experience in Burkina Faso.
These investigators adopted a similar approach to that
employed in the MenAfriCar project, utilising both con-
ventional and molecular techniques but Kristiansen et al.
were more rigorous in their application of conventional
microbiological techniques by repeating these on
meningococci sent to the NIPH.
The ELISA technique used for measuring IgG antibod-
ies to meningococcal polysaccharides has been developed
to the standard required for registration of new meningo-
coccal vaccines and transferring this technology to Africa
proved challenging. It is possible that a simpler technique
would be adequate for epidemiological studies. However,
this assay, and the SBA assay, are being used to measure
immunological correlates of protection against serogroup
A meningococcal carriage in household and longitudinal
studies and it is therefore important that the quality of
these assays meets high internationals standards.
A primary objective of the MenAfriCar consortium has
been the collection of comparable data across the centres.
The TeleForm data management adopted for the study
was new to most centres and because of lack of time for
training and frequent changes in form design at the start
of the project, completion errors and poor optical charac-
ter recognition were initially common. However, this
situation improved as form design became stable and
field workers and local data managers gained experience
and confidence in completing forms and using the system.
Slow and intermittent Internet connectivity was initially a
major challenge that led to delays in uploading local data
and synchronising local and central databases, which, in
turn, affected central monitoring. This challenge was
partially addressed by the end of the project with some
centres acquiring higher bandwidth or dedicated Internet
connection, for example, through mobile broadband, and
by others performing data upload operations in the
evening or at night. By the end of the study, all centres
were able to upload on schedule.
Initial results from evaluation of the impact of PsA-TT
in Burkina Faso are encouraging with marked drops in
the incidence of serogroup A meningitis and carriage
following introduction of the vaccine (Kristiansen et al.
2012; Novak et al. 2012). However, there will be a
continuing need to evaluate the impact of this and other
meningococcal vaccines on meningococcal carriage as
well as invasive disease in countries of the African menin-
gitis belt during the coming years. Experience gained by
members of the MenAfriCar consortium will help in
meeting this challenge.
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